Biogen is an American multinational biotechnology company headquartered in Cambridge, Massachusetts. Founded in 1978, it specializes in therapies for neurological diseases and develops medicines across neurology and related areas.
Oncotelic granted Lunai Bioworks worldwide rights to its nose-to-brain delivery system for biodefense and Alzheimer's. Nearly 98% of small-molecule drugs fail to cross the blood-brain barrier.
BIIB122 failed to slow Parkinson's progression in the Phase 2b LUMA study, missing primary and secondary endpoints. Biogen and Denali will discontinue the drug in idiopathic Parkinson's disease; Denali continues the BEACON study in LRRK2 carriers.
Biogen's Phase 2 CELIA trial showed diranersen slowed Alzheimer's decline and cut tau biomarkers, but missed the dose-response goal. Leqembi sales data is expected next quarter.
Biogen announced that litifilimab received FDA Breakthrough Therapy Designation for cutaneous lupus erythematosus and will present Phase 2 AMETHYST study results at the 2026 AAD Annual Meeting, with Phase 3 data expected in 2027.
The global precision medicine market reached $98.87 billion in 2024 and is projected to grow at 14.8% CAGR through 2033, driven by genomic sequencing advances, chronic disease prevalence, and AI-driven diagnostics adoption.
The global antibodies market is projected to reach $667.8 billion by 2032 with a 12.9% CAGR, while high throughput antibody production services are expected to grow at 11.2% CAGR through 2033, driven by biopharmaceutical development and monoclonal antibody therapeutics demand.
